Pinnacle Medicines added $89 million to fund peptide drugs designed to combine biologic-like efficacy with oral small-molecule dosing convenience. The startup’s lead program—built within OrbiMed-incubated Pinnacle—aims to enter the clinic in asthma and chronic obstructive pulmonary disease. The financing targets a core differentiation strategy for the company: peptides that are orally administered yet retain functional performance more typical of injectable biologics. The report links the near-term clinical plan to an emphasis on dosing convenience and broader patient access. For the sector, the round reflects continuing investor appetite for modality innovation where dosing route is a practical barrier. It also positions Pinnacle to compete in oral peptide and “biologic-like” small-molecule/peptide spaces as late-stage oral development continues to attract capital.